DARPA Antibody Technology Program, Phase II: Characterization of an Anti-HA33A Human Immunoglobulin G Antibody Produced by AnaptysBio, Inc.
Abstract
The Defense Advanced Research Projects Agency (DARPA; Arlington, VA) Antibody Technology Program (ATP) focused on development of technologies that enhance the thermal stability and binding affinity of a given antibody. The U.S. Army Edgewood Chemical Biological Center (ECBC; now known as U.S. Army Combat Capabilities Development Command Chemical Biological Center; Aberdeen Proving Ground, MD) functioned as an independent laboratory to provide technical support on immune reagents and assist in defining the government-supplied antibody antigen pairs. Project goals were to (1) implement standardized methods for characterizing antibodies developed at ECBC with de novo thermal and binding properties of select reagents for use by DARPA-funded investigators, and (2) use those methods to validate changes in antibody thermal stability and binding affinities achieved by DARPA investigators. Because combinatorial approaches to antibody enhancement are random and may lead to fortuitous improvements in stability or affinity, ATP enhancement strategies were required to be transferable to other antibody molecules. The Bot 56 antibody, which detects HA33 of BOTA, was chosen for enhancement. The focus was evaluation of the Bot antibody supplied by AnaptysBio, Inc. (San Diego, CA) for affinity and stability enhancements. Results of this study include standardized parametric data on antibody properties and performance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2019
- Accession Number
- AD1074350
Entities
People
- Alena M. Calm
- Candice Warner
- Darrel Menking
- Heather Welsh
- James Carney
- Melody Zacharko
- Patricia E. Buckley
- Roy Thompson